Anemia of Chronic Disease

• Hepcidin-Mediated Iron Sequestration: Hepcidin, a 25-amino acid peptide hormone synthesized by hepatocytes, is the master regulator of systemic iron homeostasis. In chronic inflammation, elevated interleukin-6 (IL-6) activates the JAK-STAT3 pathway in hepatocytes, leading to increased hepcidin transcription. Elevated hepcidin increases the internalization and degradation of ferroportin, the sole iron exporter on enterocytes and macrophages, trapping iron within macrophages of the reticuloendothelial system. This creates functional iron deficiency despite normal or elevated ferritin levels—iron cannot be mobilized to the bone marrow erythroid precursors despite adequate total body iron stores. This mechanism is distinct from absolute iron deficiency, where total body iron is depleted.

• Blunted Erythropoietin Response and EPO Resistance: Multiple mechanisms impair the normal erythropoietic response. Chronic inflammation suppresses renal erythropoietin (EPO) production through activation of hepcidin and other inflammatory mediators, resulting in relatively low EPO levels for the degree of anemia. Additionally, inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and IL-6 induce EPO resistance by downregulating erythroid progenitor expression of the EPO receptor and by promoting apoptosis of erythroid precursor cells. The combination of reduced EPO production and reduced bone marrow responsiveness creates a "double hit" on erythropoiesis.

• Direct Suppression of Erythroid Progenitor Growth: Inflammatory cytokines directly suppress erythroid progenitor proliferation and differentiation. TNF-α inhibits burst-forming units-erythroid (BFU-E) and colony-forming units-erythroid (CFU-E) growth in vitro and in vivo. Macrophage-derived cytokines promote apoptosis in erythroid precursor cells and reduce their response to growth factors. Additionally, hepcidin itself has direct toxicity to erythroid progenitors independent of iron sequestration. The net result is reduced reticulocyte count relative to the degree of anemia (inappropriately low reticulocyte response).

• Inflammatory Activation of Macrophages: Chronic stimulation of tissue macrophages by persistent antigen presentation or pathogen-associated molecular patterns leads to increased production of TNF-α, IL-6, and IL-1β. These macrophages accumulate iron that cannot be released due to ferroportin degradation, further reducing circulating iron availability. In certain conditions such as tuberculosis or fungal infections, macrophage activation is particularly pronounced.

• Shortened Red Cell Lifespan (Variable Component): Some chronic inflammatory conditions produce mild reduction in red blood cell survival through immune-mediated mechanisms or splenic sequestration, though this is typically not the dominant mechanism in uncomplicated ACD. Hemolytic markers are usually normal or only minimally abnormal.

• Abnormalities in Iron Sensing and Signaling: Beyond IL-6/STAT3, other signaling pathways contribute. Bone morphogenetic protein 6 (BMP6), normally the primary regulator of hepcidin in iron-replete states, may be dysregulated. Additionally, persistent activation of Toll-like receptors (TLRs) and NOD-like receptors in chronic inflammation augments inflammatory cytokine production independent of iron status, creating a self-perpetuating cycle of hepcidin elevation.

• Chronic Infections: Tuberculosis, chronic osteomyelitis, bacterial endocarditis, chronic pyelonephritis, fungal infections (histoplasmosis, coccidioidomycosis), and chronic viral infections including HIV and hepatitis C are classic causes. Tuberculosis is historically one of the most common infectious causes of ACD worldwide, with disease duration of months to years typically required for anemia development.

• Autoimmune and Inflammatory Conditions: Rheumatoid arthritis (one of the most common causes in developed countries), systemic lupus erythematosus, inflammatory bowel disease (Crohn's disease and ulcerative colitis), vasculitis syndromes, and chronic hepatitis represent major causes. The degree of anemia in rheumatoid arthritis often correlates with disease activity markers such as C-reactive protein and erythrocyte sedimentation rate.

• Malignancy: Both hematologic (lymphoma, chronic leukemias, multiple myeloma) and solid tumors (renal cell carcinoma, lung cancer, gastric cancer) produce ACD through production of inflammatory cytokines and IL-6 in particular. Renal cell carcinoma classically produces IL-6, and patients may have anemia despite normal renal function. Anemia in cancer patients is multifactorial, often combining ACD with chemotherapy-induced bone marrow suppression, bleeding, and nutritional deficiencies.

• Chronic Kidney Disease: CKD produces anemia through multiple mechanisms, with ACD often coexisting with erythropoietin deficiency (the primary mechanism in advanced CKD) and iron deficiency from urinary losses and phlebotomy. The distinction becomes important for treatment decisions. Uremia itself may contribute to red cell hemolysis and bone marrow suppression.

• Obesity and Metabolic Syndrome: Chronic low-grade inflammation in obesity drives elevated hepcidin and mild ACD. Adipose tissue serves as an endocrine organ producing IL-6 and TNF-α.

• Aging: Advanced age is associated with chronic elevation of inflammatory markers ("inflammaging"), and ACD contributes to the high prevalence of anemia in older adults.

• Type 2 Diabetes Mellitus: Chronic hyperglycemia and associated inflammation predispose to ACD independent of renal impairment.

• Fatigue and Dyspnea: These are the most common symptoms but are often overshadowed by symptoms of the underlying condition. Fatigue is multifactorial, resulting from reduced oxygen delivery, inflammatory cytokine effects (particularly TNF-α and IL-6), and often comorbid depression in chronic illness. Dyspnea on exertion may be mild, as the slow development of anemia allows some compensatory increase in cardiac output and peripheral oxygen extraction. Patients with concurrent cardiopulmonary disease experience dyspnea more prominently.

• Reduced Exercise Tolerance and Functional Decline: Patients report decreased ability to perform usual activities, though this is often attributed to the underlying disease. In elderly patients or those with marginal cardiac function, even modest anemia may precipitate symptomatic limitation.

• Pallor: Conjunctival, palmar, and mucosal pallor may be observed on examination, though this is less reliable than hemoglobin measurement. Pallor may be masked in patients with dark skin pigmentation or in those with concurrent inflammation causing erythema.

• Tachycardia and Flow Murmurs: Compensatory tachycardia develops to maintain cardiac output. A systolic flow murmur may be audible, particularly if anemia is moderate (Hgb <8 g/dL). These findings reflect increased cardiac output to compensate for reduced oxygen-carrying capacity.

• Absence of Splenomegaly: Unlike hemolytic anemias or thalassemia trait, ACD typically does not produce splenomegaly, which serves as a helpful distinguishing feature. Splenomegaly, if present, suggests an alternative etiology such as concomitant myeloproliferative disease, lymphoma, or hemolysis.

• Symptoms Attributable to Underlying Disease: The clinical presentation is dominated by manifestations of the chronic condition (fever and weight loss in tuberculosis, joint pain and stiffness in rheumatoid arthritis, constitutional symptoms in malignancy, etc.), and anemia may be discovered incidentally on laboratory evaluation.

• Clinical Variants: Patients with concurrent iron deficiency (from blood loss or poor nutritional intake), vitamin B12 or folate deficiency, or bone marrow suppression from chemotherapy present with more severe anemia and may have additional manifestations such as glossitis or neuropathy.

• Complete Blood Count (CBC) Interpretation: ACD typically presents with normocytic anemia (mean corpuscular volume 80-100 fL), though microcytic anemia (MCV <80 fL) develops in approximately 25-50% of cases due to iron sequestration and functional iron deficiency. Hemoglobin concentration is usually mild-to-moderate (7-11 g/dL, rarely <7 g/dL unless complicated). The reticulocyte count is inappropriately low relative to the degree of anemia—absolute reticulocyte count is typically <100,000/μL and reticulocyte index (reticulocyte % × patient Hct / normal Hct) is <2, reflecting blunted erythropoietic response. This low reticulocyte response is the hallmark distinguishing ACD from hemolytic anemia (which produces brisk reticulocytosis) and from acute blood loss (which produces reactive reticulocytosis). White blood cell and platelet counts are typically normal unless the underlying disease affects these lineages.

• Iron Metabolism Parameters: This is the critical diagnostic category. Serum ferritin is elevated or normal (typically >100 ng/mL), reflecting macrophage iron storage and the acute-phase response (ferritin is an acute-phase reactant). Serum iron is low (<60 μg/dL), and transferrin saturation is low (<20%), creating the picture of low iron with high ferritin—the classic signature of functional iron deficiency. Total iron-binding capacity (TIBC) is low or normal, distinguishing ACD from absolute iron deficiency (where TIBC is elevated). Serum soluble transferrin receptor level may be normal or only mildly elevated, providing additional discrimination from absolute iron deficiency (where it is significantly elevated). The combination of low serum iron, low TIBC, elevated ferritin, and low transferrin saturation is highly specific for ACD.

• Inflammation Markers: Elevated acute-phase reactants support the inflammatory etiology. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typically elevated, reflecting underlying inflammatory disease. These correlate with disease activity and hepcidin levels. In some conditions (such as systemic lupus erythematosus), ESR may be disproportionately elevated relative to CRP.

• Serum Erythropoietin (EPO) Level: EPO is relatively low or inappropriately normal for the degree of anemia. In uncomplicated anemia, EPO typically rises to 500-1000 mIU/mL or higher when hemoglobin falls below 10 g/dL. In ACD, EPO levels are typically <500 mIU/mL, demonstrating the inadequate EPO response to anemia. This distinguishes ACD from primary bone marrow disease (where EPO is elevated) and from chronic kidney disease alone (where EPO is severely deficient relative to renal function).

• Hepcidin Measurement: Serum hepcidin-25 is elevated in ACD, often >100 ng/mL (normal <150 ng/mL varies by laboratory, but ACD patients are at the high end). Hepcidin measurement is not routinely performed clinically but is valuable in research settings and increasingly available in specialized laboratories. Elevated hepcidin in the setting of anemia is pathognomonic for ACD.

• Bone Marrow Examination: Bone marrow examination is rarely necessary but, when performed, reveals adequate or increased iron stores (distinguishing from absolute iron deficiency), adequate or increased cellularity (distinguishing from aplastic anemia or myelodysplastic syndrome), and adequate numbers of erythroid precursors with normal maturation (distinguishing from primary bone marrow disease). Prussian blue staining demonstrates macrophage iron stores, which are abundant. Bone marrow biopsy is reserved for cases with atypical features or diagnostic uncertainty.

• Diagnostic Criteria Summary: ACD is diagnosed when the following constellation is present: (1) chronic underlying inflammatory, infectious, or neoplastic disease of ≥1-2 months duration; (2) mild-to-moderate anemia (Hgb 7-11 g/dL); (3) normocytic or microcytic anemia; (4) low reticulocyte index (<2); (5) elevated or normal ferritin; (6) low serum iron and low TIBC; (7) elevated CRP or ESR; (8) normal or elevated bone marrow iron stores (if examined); (9) relatively low EPO level for degree of anemia. No single test is diagnostic; rather, the constellation of findings in the appropriate clinical context establishes the diagnosis.

• Differential Diagnosis Considerations: Absolute Iron Deficiency presents with microcytic anemia, low ferritin (<15 ng/mL), elevated TIBC, elevated transferrin saturation, and often elevated reticulocyte response; clinical history reveals blood loss or malabsorption. Anemia of Chronic Kidney Disease occurs with GFR <45 mL/min/1.73m² and presents with severe EPO deficiency (EPO levels often <10 mIU/mL); however, renal anemia frequently coexists with ACD. Thalassemia Trait is microcytic with normal or elevated ferritin but has normal or elevated reticulocyte count, normal RDW, elevated HbA2 on hemoglobin electrophoresis, and family history. Mixed Anemia (ACD + iron deficiency or ACD + B12 deficiency) is common and requires assessment of additional parameters such as methylmalonic acid and homocysteine for B12 status. Sideroblastic Anemia and Myelodysplastic Syndrome may present similarly but are distinguished by bone marrow findings (ringed sideroblasts or dysplasia, respectively).

• Treatment of Underlying Disease (First-Line): The most important intervention is aggressive management of the chronic inflammatory, infectious, or neoplastic condition. Control of disease activity often leads to normalization of inflammatory markers, reduction in hepcidin, and gradual improvement in anemia. In rheumatoid arthritis, effective anti-TNF therapy often improves hemoglobin by 1-2 g/dL. In tuberculosis, successful antimicrobial therapy leads to anemia resolution over months. In malignancy, treatment of the primary tumor may improve anemia. This underscores the importance of recognizing ACD as a marker of disease activity rather than a primary hematologic problem.

• Hepcidin Antagonism (Emerging Targeted Therapy): Luspatercept is a transforming growth factor-beta (TGF-β) pathway inhibitor that increases late-stage erythroid progenitor proliferation and reduces hepcidin expression, improving anemia in ACD. It is administered as a subcutaneous injection every 3 weeks, with dose escalation from 0.75 mg/kg based on response. Luspatercept has demonstrated efficacy in reducing transfusion requirements and improving hemoglobin in patients with ACD, particularly those with moderate-to-severe anemia. The drug is increasingly used in clinical practice, particularly for patients whose underlying disease is well-controlled but anemia persists. Additional hep

Complications of the anemia itself

• Demand-ischemia and decompensation of comorbid disease: reduced oxygen-carrying capacity plus compensatory tachycardia raises myocardial oxygen demand while shortening diastolic coronary filling time. In patients with obstructive CAD, aortic stenosis, or heart failure this can precipitate type 2 myocardial infarction, angina, or pulmonary edema — chest pain, new ischemic ECG changes, or a troponin rise in an anemic inpatient is an emergency.
• Functional decline and falls in older adults: reduced oxygen delivery plus inflammatory cytokine burden; signaled by new gait instability or delirium rather than by hemoglobin alone.
• Marker of uncontrolled underlying disease: worsening anemia with rising CRP/ESR usually means the driving inflammatory, infectious, or neoplastic process is progressing, not that a new hematologic disease has appeared.
• Missed second diagnosis: because ferritin is an acute-phase reactant, coexisting absolute iron deficiency (and its cause) can be masked. A new iron-deficient picture in an adult mandates GI evaluation, per the American College of Gastroenterology guidance on iron deficiency anemia — failing to do so risks missing colorectal cancer.

Complications of therapy

• Erythropoiesis-stimulating agents (ESAs): carry an FDA boxed warning for death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression/shortened survival in cancer; hypertension and seizures are additional labeled warnings rather than boxed-warning items. Mechanism is hyperviscosity plus off-target EPO-receptor signaling. KDIGO advises against targeting normal hemoglobin in CKD, and the ASCO/ASH guideline restricts ESAs largely to palliative-intent chemotherapy-induced anemia. New focal deficit, limb swelling, or accelerating blood pressure are the warning findings; stroke is an emergency.
• Pure red cell aplasia from neutralizing anti-EPO antibodies: sudden loss of reticulocytes with transfusion dependence.
• Intravenous iron: hypersensitivity/anaphylaxis (emergency — treat with intramuscular epinephrine 0.3 mg); also hypophosphatemia, classically with ferric carboxymaltose, which can cause osteomalacia.
• Unnecessary oral iron: largely ineffective in ACD because hepcidin degrades enterocyte ferroportin, so unabsorbed iron simply causes constipation, nausea, and non-adherence, with possible mucosal and gut-microbiome effects. Parenchymal iron loading is a concern with repeated parenteral iron or chronic transfusion, not with oral iron in an iron-restricted inflammatory state.
• Transfusion: TACO, TRALI, alloimmunization, and iron overload. AABB recommends a restrictive threshold; transfusing chronic, well-compensated ACD to a "normal" hemoglobin adds risk without benefit.

• The iron panel signature: low serum iron, low TIBC, normal-to-high ferritin, low transferrin saturation. Iron deficiency anemia gives low iron, HIGH TIBC, low ferritin. TIBC direction is the most useful single discriminator on a classic exam iron panel — transferrin is a negative acute-phase reactant, so inflammation drives it down while it rises in true iron deficiency. In real practice ferritin combined with soluble transferrin receptor outperforms TIBC, and a low TIBC can also reflect malnutrition or hepatic dysfunction.
• Hepcidin is the answer to the mechanism question: IL-6 → JAK-STAT3 → hepatocyte hepcidin → internalization and degradation of ferroportin → iron trapped in macrophages and enterocytes. The stem often disguises this as "iron trapped in the reticuloendothelial system."
• Normocytic first, microcytic later: ACD is most often normocytic; the microcytic version appears only after prolonged iron restriction. A markedly low MCV with a very high RBC count and near-normal RDW should redirect you toward thalassemia trait.
• Ferritin thresholds for coexisting absolute iron deficiency: a ferritin below roughly 15 ng/mL is highly specific for depleted stores, below about 30 ng/mL is the commonly used sensitive cut-off, and in CKD or active inflammation thresholds up to about 100 ng/mL (with transferrin saturation <20%) are applied because inflammation can only push ferritin up, never down. When ferritin is intermediate, the soluble transferrin receptor / log-ferritin index identifies coexisting iron deficiency; sTfR is high in true deficiency and normal in pure ACD.
• Single best next step: identify and treat the underlying inflammatory, infectious, or malignant process. Reflexively starting oral iron is the classic wrong answer — hepcidin blocks enterocyte ferroportin, so oral iron is poorly absorbed and will not correct pure ACD.
• Reticulocyte index <2 — hypoproliferative. Brisk reticulocytosis argues for hemolysis or blood loss, not ACD.
• The association examiners love: rheumatoid arthritis (and IL-6–secreting renal cell carcinoma) as the prototype driver; anemia severity tracks disease activity.
• ESA restraint: per KDIGO in CKD and ASCO/ASH in cancer, do not aim for a normal hemoglobin — thrombosis, stroke, and worse cancer outcomes are the tested harms. Correct iron status before or alongside any ESA.